Ruxandra Draghia-Akli

Ruxandra Draghia-Akli

M.D., Ph.D. Former EVP, Head of Research & DevelopmentatNovavax· In the 2025 proxy

Pay in FY2025Novavax stock -16.4% the same year

Ruxandra Draghia-Akli was paid $2.3M in FY2025 (Dec). Novavax stock fell 16.4% that year.

Pay$100 in the stock at the end of FY24 → $84
Pay is from the Summary Compensation Table of each Novavax proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NovavaxPublic company · 1 yr
    • M.D., Ph.D. Former EVP, Head of Research & Development2025 – Present · 1 yrStock in role +21%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?